| pubmed-article:20142722 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:20142722 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:20142722 | lifeskim:mentions | umls-concept:C0812413 | lld:lifeskim |
| pubmed-article:20142722 | lifeskim:mentions | umls-concept:C0246415 | lld:lifeskim |
| pubmed-article:20142722 | lifeskim:mentions | umls-concept:C0045093 | lld:lifeskim |
| pubmed-article:20142722 | lifeskim:mentions | umls-concept:C2607850 | lld:lifeskim |
| pubmed-article:20142722 | lifeskim:mentions | umls-concept:C0282460 | lld:lifeskim |
| pubmed-article:20142722 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:20142722 | lifeskim:mentions | umls-concept:C0205171 | lld:lifeskim |
| pubmed-article:20142722 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:20142722 | pubmed:dateCreated | 2011-1-28 | lld:pubmed |
| pubmed-article:20142722 | pubmed:abstractText | The combinations of cisplatin-pemetrexed and cisplatin-gemcitabine are considered the standard systemic therapy for malignant pleural mesothelioma (MPM), which is a rapidly progressive tumor. The purpose of the present study is to evaluate the efficacy, safety, and clinical benefit of the gemcitabine plus docetaxel regimen in the second-line treatment of this disease. | lld:pubmed |
| pubmed-article:20142722 | pubmed:language | eng | lld:pubmed |
| pubmed-article:20142722 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20142722 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:20142722 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20142722 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20142722 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20142722 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20142722 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20142722 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:20142722 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:20142722 | pubmed:issn | 1537-453X | lld:pubmed |
| pubmed-article:20142722 | pubmed:author | pubmed-author:KotanidouAnas... | lld:pubmed |
| pubmed-article:20142722 | pubmed:author | pubmed-author:SyrigosKostas... | lld:pubmed |
| pubmed-article:20142722 | pubmed:author | pubmed-author:AlamaraChrist... | lld:pubmed |
| pubmed-article:20142722 | pubmed:author | pubmed-author:CharpidouAndr... | lld:pubmed |
| pubmed-article:20142722 | pubmed:author | pubmed-author:TourkantonisI... | lld:pubmed |
| pubmed-article:20142722 | pubmed:author | pubmed-author:MakriliaNekta... | lld:pubmed |
| pubmed-article:20142722 | pubmed:author | pubmed-author:TsimpoukisSot... | lld:pubmed |
| pubmed-article:20142722 | pubmed:author | pubmed-author:RalliMariaM | lld:pubmed |
| pubmed-article:20142722 | pubmed:author | pubmed-author:NikolaidisIli... | lld:pubmed |
| pubmed-article:20142722 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:20142722 | pubmed:volume | 34 | lld:pubmed |
| pubmed-article:20142722 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:20142722 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:20142722 | pubmed:pagination | 38-42 | lld:pubmed |
| pubmed-article:20142722 | pubmed:meshHeading | pubmed-meshheading:20142722... | lld:pubmed |
| pubmed-article:20142722 | pubmed:meshHeading | pubmed-meshheading:20142722... | lld:pubmed |
| pubmed-article:20142722 | pubmed:meshHeading | pubmed-meshheading:20142722... | lld:pubmed |
| pubmed-article:20142722 | pubmed:meshHeading | pubmed-meshheading:20142722... | lld:pubmed |
| pubmed-article:20142722 | pubmed:meshHeading | pubmed-meshheading:20142722... | lld:pubmed |
| pubmed-article:20142722 | pubmed:meshHeading | pubmed-meshheading:20142722... | lld:pubmed |
| pubmed-article:20142722 | pubmed:meshHeading | pubmed-meshheading:20142722... | lld:pubmed |
| pubmed-article:20142722 | pubmed:meshHeading | pubmed-meshheading:20142722... | lld:pubmed |
| pubmed-article:20142722 | pubmed:meshHeading | pubmed-meshheading:20142722... | lld:pubmed |
| pubmed-article:20142722 | pubmed:meshHeading | pubmed-meshheading:20142722... | lld:pubmed |
| pubmed-article:20142722 | pubmed:meshHeading | pubmed-meshheading:20142722... | lld:pubmed |
| pubmed-article:20142722 | pubmed:meshHeading | pubmed-meshheading:20142722... | lld:pubmed |
| pubmed-article:20142722 | pubmed:meshHeading | pubmed-meshheading:20142722... | lld:pubmed |
| pubmed-article:20142722 | pubmed:meshHeading | pubmed-meshheading:20142722... | lld:pubmed |
| pubmed-article:20142722 | pubmed:meshHeading | pubmed-meshheading:20142722... | lld:pubmed |
| pubmed-article:20142722 | pubmed:meshHeading | pubmed-meshheading:20142722... | lld:pubmed |
| pubmed-article:20142722 | pubmed:meshHeading | pubmed-meshheading:20142722... | lld:pubmed |
| pubmed-article:20142722 | pubmed:meshHeading | pubmed-meshheading:20142722... | lld:pubmed |
| pubmed-article:20142722 | pubmed:meshHeading | pubmed-meshheading:20142722... | lld:pubmed |
| pubmed-article:20142722 | pubmed:meshHeading | pubmed-meshheading:20142722... | lld:pubmed |
| pubmed-article:20142722 | pubmed:meshHeading | pubmed-meshheading:20142722... | lld:pubmed |
| pubmed-article:20142722 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:20142722 | pubmed:articleTitle | Phase II study of gemcitabine plus docetaxel as second-line treatment in malignant pleural mesothelioma: a single institution study. | lld:pubmed |
| pubmed-article:20142722 | pubmed:affiliation | Oncology Unit, Third Department of Medicine, Sotiria General Hospital, Athens School of Medicine, Greece. | lld:pubmed |
| pubmed-article:20142722 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:20142722 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
